Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...

United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.